



The
Patent
Office

PCT/GB 99/01461



GB99/1461

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 15 JUN 1999


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




P. Mahoney

Signed

Dated 3 June 1999

THIS PAGE BLANK (USPTO)



1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference HL59644/000/LCS

2. Patent application number
(The Patent Office will fill in this part)

9812316.9

3. Full name, address and postcode of the or of each applicant (underline all surnames)

University of Bristol
Senate House
Tyndall Avenue
Bristol
BS8 1TH

Patents ADP number (if you know it)
If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

793131001

4. Title of the invention
CANCER VACCINES

5. Full name of your agent (if you have one)

Haseltine Lake & Co.

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Imperial House
15-19 Kingsway
London WC2B 6UD

34001

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day/month/year)

8. Is a statement of inventorship and of right to a grant of patent required in support of this request? (Answer "Yes" if:
a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.

Yes

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	0
Description	5
Claim(s)	1
Abstract	0
Drawing(s)	0

10. If you are also filing any of the following, state how many against each item.

Priority documents	0
Translations of priority documents	0
Statement of inventorship and right to a grant of patent (Patents Form 7/77)	0
Request for preliminary examination and search (Patents Form 9/77)	1
Request for substantive examination (Patents Form 10/77)	0
Any other documents. (please specify)	0

11. I/We request the grant of a patent on the basis of this application

Signature

Harettine Lake Ho.
(DAN)

Date
5th June 1998

12. Name and daytime telephone number of person to contact in the United Kingdom

Dr. L.C. Sealy

[0117] 9260197

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered "Yes" Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

CANCER VACCINES

The present invention relates to vaccines for a variety of diseases, particularly cancers, in which Epstein-Barr virus (EBV) has, or is believed to have, a causative role, and therapies for treatment of such diseases.

BACKGROUND

EBV is one of the eight known human herpes viruses. Infection usually occurs in early childhood; however, clinical symptoms are usually weak or undetectable at this stage. Primary infection with EBV later in life is associated with infectious mononucleosis (IM), which is the second most frequent disease in adolescence in the US. EBV also has oncogenic potential. There is a strong link between EBV and endemic Burkitt's lymphoma (BL) and undifferentiated nasopharyngeal carcinoma (NPC). Also, a large proportion of lymphomas that occur in immunocompromised patients are caused by EBV, and an association has been shown to exist between certain Hodgkin's lymphomas and EBV.

Latently EBV-infected cells express a small number of so-called "latent" proteins. These include six nuclear proteins (EBNAs 1, 2, 3A, 3B, 3C and -LP), three integral membrane proteins (LMP-1, 2A and 2B) and two non-polyadenylated virus derived RNAs (EBERs) with a role in RNA splicing.

EBV latent membrane protein 1 (LMP-1) is present in the plasma membrane of infected cells. It is also expressed in nasopharyngeal carcinomas (NPCs) and EBV-positive Hodgkin's lymphomas (HD) which indicates a role for LMP-1 in the development of these tumours. The LMP-1 gene can alter the phenotype of uninfected cells causing the upregulation of cell surface activation markers, promoting cell proliferation. LMP-1 can also alter signalling pathways and has anti-

apoptotic effects. An cellular immune response directed against this viral antigen has not been demonstrated with any degree of certainty in either healthy carriers or tumour patients.

5 Many animal viruses have evolved mechanisms to avoid detection by the host immune system. Commonly, these mechanisms involve interference with the TAP-associated peptide translocation system. It is thought that EBV has also evolved similar mechanisms to avoid
10 immune system detection, thus allowing its persistence in the host. This explains why certain cellular immune responses are not detectable to the EBV latent protein EBNA1 and could explain the apparent absence of such responses against LMP1.

15 The heat-labile enterotoxin of *E. coli* (Etx) and its homologue cholera toxin (Ctx) are composed of a single A subunit and five identical B subunits. The A subunit is toxic, exhibiting adenosine diphosphate (ADP)-ribosyl transferase activity. The B subunits
20 (CtxB and EtxB) are non-toxic lectins that bind the cell surface glycolipid, ganglioside GM1, with high affinity and specificity, and cross-link it.

Binding of GM1 by EtxB has been shown to induce differential affects on lymphocyte populations,
25 including a specific depletion of CD8⁺ T-cells and an associated activation of B cells. WO 97/02045 (Williams et al.) discloses the use of agents such as EtxB for the treatment of autoimmune diseases, leukaemia's of T-cell origin, and for use in the
30 prevention of transplantation rejection and graft versus host disease (GVHD).

THE INVENTION

According to a first aspect of the invention there is provided a vaccine composition which comprises:

- 35 a) EtxB, CtxB, or an agent other than EtxB or CtxB which has GM1-binding activity; and

b) an EBV antigen
for use in the treatment and/or prevention of EBV-associated diseases.

According to a second aspect of the invention
5 there is provided a therapeutic composition which
comprises:

EtxB, CtxB or an agent other than EtxB or CtxB
which has GM1-binding activity
for use in the treatment of EBV-associated
10 diseases.

Based on experiments carried out by the inventor
which show that EtxB cocaps with LMP1, and that EtxB
promotes fragmentation of LMP-1, it is theorised that
EtxB (and other agents like CtxB having GM1 binding
15 activity) will be useful to stimulate anti-EBV immune
responses. This activity has applications in vaccines
to prevent EBV associated diseases, and in therapeutic
treatments to treat such diseases once they have
developed.

20 Without wishing to be bound by theory, it is
believed that when EtxB cocaps with LMP-1 the antigen
is processed by a different intracellular route, which
enables the antigen to by-pass the normal processing
route which is blocked by the virus. The antigen is
25 thus presented efficiently on the cell surface. The
action of EtxB may also cause different epitopes of the
antigen to be presented at the cell surface, from those
which are presented if the antigen were processed by
the conventional route.

30 The vaccine of the invention may be used to
prevent infection by EBV, or development of EBV-
associated diseases in EBV-infected individuals. The
vaccine may also comprise a separate adjuvant, or the
agent (such as EtxB or CtxB) can act as an adjuvant in
35 its own right.

The agents specified in the second aspect of the

present invention may be used alone (i.e. without antigen) in the treatment of a EBV-associated disease which has already developed in a subject.

5 The terms "CtxB" and "CtxB" as used herein include natural and recombinant forms of the molecule. The recombinant form is particularly preferred, because it is in a pure form without any associated toxic A subunit. The terms also include mutant molecules and other synthetic molecules (containing parts of CtxB or 10 CtxB) which retain the desired properties of CtxB or CtxB. Agents other than CtxB and CtxB which retain GM1-binding activity include antibodies which bind GM1. Humanised monoclonal antibodies are especially preferred. In all aspects of the invention, the agent 15 having GM1-binding activity may also be capable of cross-linking GM1 receptors. CtxB is one such agent which is capable of cross-linking GM1 receptors by virtue of its pentameric form.

20 The preferred agent for use in the invention is CtxB.

The EBV antigen is an antigen derivable from EBV itself or an antigen which is caused to be expressed by an EBV-infected host cell by the action of EBV. Preferably the antigen is an EBV latent membrane 25 protein. Particularly preferred are the antigens LMP-1, LMP-2A, LMP-2B, and EBNA-1 as well as antigenic fragments thereof. The antigen may be isolated directly from EBV infected cells, or be made by synthetic or recombinant means.

30 The term "antigen" includes proteins, glycoproteins, carbohydrates and nucleic acids. For protein antigens, the antigen may be administered in the vaccine in the form of whole protein, fragments of the protein which retain antigenic activity, or 35 antigenic determinants.

The present invention is particularly suited for

the treatment and/or prevention of the following diseases: infectious mononucleosis, Burkitt's lymphoma, nasopharyngeal carcinomas, and Hodgkin's lymphomas. It is believed that the invention will be particularly suited to the treatment and/or prevention of nasopharyngeal carcinomas and Hodgkin's lymphomas.

5 The vaccine or the therapeutic composition according to the first and second aspects of the invention may be used to prevent development of, or treat, an EBV-associated disease in a mammalian subject, by administration of an immunologically effective amount to the subject.

10 The mammalian subject may be, for example, a healthy EBV-infected or uninfected individual, an immunodeficient individual, or an individual with an EBV-associated disease.

15 The vaccine may be administered by any suitable route. The agent and the antigen may be co-administered to the mammalian subject or administered separately. The agent and the antigen may be separate or linked, for example covalently or genetically linked, to form a single effective agent.

CLAIMS

1. A vaccine composition which comprises:

- a) EtxB, CtxB, or an agent other than EtxB or CtxB which has GM1-binding activity; and
- b) an EBV antigen

for use in the treatment and/or prevention of EBV-associated diseases.

2. A vaccine composition according to claim 1, which comprises EtxB.

3. A vaccine composition according to claim 1 or 2, wherein the EBV antigen is LMP-1.

4. A vaccine composition according to claim 1, 2 or 3, wherein the EBV-associated disease is a nasopharyngeal carcinoma or a Hodgkin's lymphoma.

5. A therapeutic composition which comprises: EtxB, CtxB or an agent other than EtxB or CtxB which has GM1-binding activity for use in the treatment of EBV-associated diseases.

6. A therapeutic composition according to claim 5, which comprises EtxB.

7. A therapeutic composition according to claim 5 or 6, wherein the EBV-associated disease is a nasopharyngeal carcinoma or a Hodgkin's lymphoma.